Russ Conroy

Data from the phase 1/2 ASTX727-07 study support the FDA approval of decitabine plus cedazuridine and venetoclax in this AML population.

CAR T-cell therapies and bispecific antibodies are still in their infancy, according to Barry Paul, MD.

Investigators are currently evaluating emiltatug ledadotin among patients with different solid tumors in a phase 1 trial.

The safety profile of zoldonrasib appeared to be “superb” among patients with NSCLC harboring KRAS G12D mutations, said Jonathan Wesley Riess, MD, MS.

The FDA has set a Prescription Drug User Fee Act date of January 4, 2027, for approving taletrectinib in this ROS1-positive NSCLC population.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Clearance of a novel AI platform may represent an important advance in personalizing treatments for patients with early-stage breast cancer.

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

Data showing the bioequivalence of extended-release ruxolitinib tablets vs reference ruxolitinib supported the FDA approval across multiple indications.

New developments revealed regulatory milestones for bacterial therapeutic candidates and potential efficacy with vaccine-based approaches.

A panel of experts discussed the implications of the AQUILA trial and the FDA approval of subcutaneous daratumumab in high-risk smoldering multiple myeloma.

Updated findings from the TRUST-I and TRUST-II trials may reflect the importance of molecular testing in non–small cell lung cancer therapy.

The MagnetisMM-5 study remains ongoing to assess the key secondary end point of overall survival among those with relapsed/refractory multiple myeloma.

Previous data presented at the 2026 AACR Annual Meeting demonstrate the efficacy of taletrectinib in ROS1-positive NSCLC harboring brain metastases.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases such as NSCLC and oral premalignant lesions.

The FDA has set a new Prescription Drug User Fee Act date of July 23, 2026, for subcutaneous isatuximab plus standard of care in multiple myeloma.

Findings from a phase 1 trial showed no adverse effects higher than grade 3 among those who received ruxolitinib/abemaciclib for advanced myelofibrosis.

Data from the phase 2 MATISSE trial could pave the way for CD39 and adenosine pathway inhibition in early-stage non–small cell lung cancer.

A numerical survival improvement was observed with ramucirumab plus pembrolizumab among those with squamous cell carcinoma in a phase 2 study.

Data from the phase 3 DREAMM-7 trial support the approval of belantamab mafodotin plus bortezomib and dexamethasone for patients in China.

Data from the Beamion LUNG-1 trial may help clinicians make informed decisions on HER2-targeted therapy for those with advanced or metastatic NSCLC.

Orca-T has demonstrated clear benefits in reducing graft-vs-host disease among patients with hematologic malignancies, according to Wendy Stock, MD.

All injections of JNJ-1900 have been completed according to plan so far in the phase 2 CONVERGE study, said Benjamin Cooper, MD.

The FDA has assigned a Prescription Drug User Fee Act date of October 10, 2026, for ifinatamab deruxtecan in extensive-stage small cell lung cancer.

Although not yet mature, overall survival data trended in favor of pirtobrutinib plus venetoclax/rituximab in the phase 3 BRUIN CLL-322 trial.

Involving transplant physicians early on is critical in myelofibrosis therapy, said Nicolaus Kröger, MD.

Phase 1/2 data may warrant further investigation of belantamab mafodotin plus lenalidomide/dexamethasone in randomized controlled studies.

Data from the PRESERVE-003 trial may support the use of a novel chemotherapy-free option for patients with squamous non–small cell lung cancer.

Data from the phase 1/2 ALKOVE-1 trial support the application for neladalkib in this non–small cell lung cancer population.